Targeted drug achieves 43% response rate in KRAS-mutated lung cancer
Risk factors for severe COVID-19 outcomes in a large US health care system
3 June 20222 monkeypox strains in US suggest possible undetected spread
3 June 2022Targeted drug achieves 43% response rate in KRAS-mutated lung cancer
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.
